89bio Coverage Assumed by B of A Securities at Buy
89bio Coverage Assumed by B of A Securities at Buy
Dow JonesApr 22 06:24 ET
Express News | B of A Securities Assumes 89bio at Buy, Announces Price Target of $30
Moomoo 24/7Apr 22 06:14 ET
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
89bio Enhances Board With Biopharma Veteran Martin Babler
TipRanksApr 17 16:22 ET
Express News | 89Bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
Moomoo 24/7Apr 17 16:05 ET
89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
PDF Version SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovati
89bioApr 17 00:00 ET
89bio Signs Deal for Construction of a Production Facility in China
Seeking AlphaApr 10 17:14 ET
On April 4, 2024, 89Bio Entered Into Collaboration Agreement With BiBo Biopharma Engineering - Filing
BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved. Under the Collaboration Agreement, the Company will pay BiBo
BenzingaApr 10 16:35 ET
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Seeking AlphaApr 9 10:03 ET
89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald
89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald
Dow JonesApr 5 09:33 ET
Express News | Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target
Moomoo 24/7Apr 5 09:23 ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and co
89bioApr 5 00:00 ET
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
Yahoo FinanceApr 3 19:01 ET
89bio(ETNB.US) Officer Sells US$575.15K in Common Stock
$89bio(ETNB.US)$ Officer PALEKAR ROHAN sold 52,718 shares of Common Stock on Apr 1, 2024 at an average price of $10.91 for a total value of $575.15K.Source: Announcement What is statement of changes i
moomoo NewsApr 3 16:41 ET
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing
Rohan Palekar, Director, Chief Executive Officer, on April 01, 2024, sold 52,718 shares in 89bio (ETNB) for $575,153. Following the Form 4 filing with the SEC, Palekar has control over a total of 459,
MT NewswiresApr 3 16:07 ET
Form 144 | 89bio(ETNB.US) Officer Proposes to Sell 574.93K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $89bio(ETNB.US)$ Officer ROHAN PALEKAR intends to sell 52,718 shares of its common stock on Apr 1, with a total market value of approximately $574.93K. ROHAN PALEKAR h
moomoo NewsApr 1 19:33 ET
Buy Rating Affirmed for 89bio's Pegozafermin: A Promising NASH Treatment With Strong Regulatory Endorsements
TipRanksMar 29 03:09 ET
Express News | HC Wainwright & Co. Maintains Buy on 89bio, Maintains $31 Price Target
Moomoo 24/7Mar 27 13:53 ET
89bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 170.03% HC Wainwright & Co. $31 → $31 Maintains Buy 03/13/2024 170.03% HC Wainwright & Co. $31
BenzingaMar 27 13:51 ET
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
TipRanksMar 27 12:30 ET
No Data
No Data